Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Unknown 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 97INDUSTRY 16OTHER_GOV 7UNKNOWN 6

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 3HER2 Positive Breast Cancer 2Metastatic Breast Cancer in the Brain 1HER2 Positive Metastatic Breast Cancer 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × pyrotinib × Clear all
NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Henan Cancer Hospital

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT06475443 2024-06-26

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Henan Cancer Hospital

Phase 2 Not yet recruiting
32 enrolled
Breast

Metastatic Breast Cancer in the Brain

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

Henan Cancer Hospital

Phase 2 Unknown
41 enrolled
Breast

Breast Neoplasms

NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡